
    
      Improve mortality and morbidity in patients with symptomatic chronic post-infarction heart
      failure under full dose conventional medical and device treatment including resynchronization
      therapy, by single versus repeated intracoronary infusion of autologous bone marrow-derived
      mononuclear cells.
    
  